This review supports the conclusion that the use of testosterone replacement therapy for the treatment of the symptoms of androgen deficiency in aging males (ADAM) may be appropriate if undertaken with due caution. The best safety data exists for using oral therapy with testosterone undeconoate. Less data exists for the treatment of postmenopausal women with testosterone. Tibolone (an estrogen--prostagen--testosterone) compound, may make the need for testosterone being added to estrogen in women unnecessary. Less data is available to support the use of DHEA or its sulfate or pregnenolone. Further studies are clearly necessary in all these areas. However, it may be tentatively concluded that we are at the dawning of the age of androgens.